Increased perfusion, improved insulin delivery and cardioprotective features of VEGF-B may be of particular benefit for patients with T2DM and ischaemic heart disease if future clinical and translational researches confirm these effects in humans and VEGF-B proves safe for human use. This evidence concerns the gene INS and heart disorder.